Bertulfo, K., Perez-Duran, P., Miller, H., Ma, C., Ambesi-Impiombato, A., Samon, J., Mackey, A., Lin, W.-H. W., Ferrando, A. A., & Palomero, T. (2025). Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences, 122(14). https://doi.org/10.1073/pnas.2426742122

Heck, C. J., Kripke, K., Dam, A., Torres-Rueda, S., Bozzani, F., Obermeyer, C., Yohannes, K., Deacon, J., Meyers, K., Quigee, D., Wiant, S., Forsythe, S., Malati, C., Larson, M., Sobieszczyk, M. E., & Castor, D. (2024). Leveraging international stakeholders’ experiences with oral PrEP costs to accelerate implementation of the monthly dapivirine vaginal ring: A qualitative study. Health Research Policy and Systems, 22(1). https://doi.org/10.1186/s12961-024-01240-5

Rafic, E., Ma, C., Shih, B. B., Miller, H., Yuste, R., Palomero, T., & Etchenique, R. (2024). RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society, 146(19), 13317–13325. https://doi.org/10.1021/jacs.4c01720

Buch, M. H., Bhatt, D. L., Charles-Schoeman, C., Giles, J. T., Mikuls, T., Koch, G. G., Ytterberg, S., Nagy, E., Jo, H., Kwok, K., Connell, C. A., Masri, K. R., & Yndestad, A. (2024). Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open, 10(2), e003912. https://doi.org/10.1136/rmdopen-2023-003912

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Ruperto, N., Brunner, H. I., Synoverska, O., Ting, T. V., Mendoza, C. A., Spindler, A., Vyzhga, Y., Marzan, K., Grebenkina, L., Tirosh, I., Imundo, L., Jerath, R., Kingsbury, D. J., Sozeri, B., Vora, S. S., Prahalad, S., Zholobova, E., Butbul Aviel, Y., Chasnyk, V., … Weiss, J. (2021). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet, 398(10315), 1984–1996. https://doi.org/10.1016/s0140-6736(21)01255-1